Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added a Study Results section and a Publications entry (Biomarker Research 2022) for pembrolizumab activity in Fanconi anemia pathway tumors on the Study Details page.
    Difference
    0.5%
    Check dated 2025-11-03T00:59:42.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    32 days ago
    Change Detected
    Summary
    Summary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.
    Difference
    4%
    Check dated 2025-10-05T09:18:43.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive changes.
    Difference
    0.1%
    Check dated 2025-09-28T03:07:26.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1, indicating a newer release. The 'Back to Top' link was removed, which is a minor UI change.
    Difference
    0.2%
    Check dated 2025-09-13T16:54:41.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-06T14:30:33.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed information about locations and various medical terms, while adding a facility name and a new version revision.
    Difference
    2%
    Check dated 2025-08-30T11:15:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.